SyntheticMR’s software solution SyMRI receives regulatory approval in Saudi Arabia and Thailand

SyntheticMR announced today that their quantitative imaging software solution SyMRi has received regulatory approval in both Saudi Arabia and Thailand.

“We are delighted to be able to introduce SyMRI to both Saudi Arabia and Thailand,” says Ulrik Harrysson, CEO, SyntheticMR. “This further develops the global presence of SyntheticMR and follows regulatory clearance for SyMRI in Japan and Brazil, both of which were confirmed during 2020.”

SyMRI provides multiple contrast weighted images and quantitative information about the patient in a single 5-6 minute scan, enabling users to speed up their imaging workflow and add objective decision support to their practice. SyMRI is the first product on the market to provide segmentation and measurements of myelin volumes. The volume measurements in SyMRI NEURO offer unique capabilities to track a patient’s development and compare values.

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB’s product SyMRI® delivers multiple contrast images and quantitative data from a single 6-minute scan. The product is available in different packages. SyMRI IMAGE supports faster MRI workflows and improved patient throughput. SyMRI NEURO delivers automatic segmentation of brain tissue, supporting objective decision support. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com.